WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia
Yıl: 2021 Cilt: 31 Sayı: 3 Sayfa Aralığı: 139 - 145 Metin Dili: İngilizce DOI: 10.4999/uhod.215031 İndeks Tarihi: 01-06-2023
WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia
Öz: According to newly defined features of bone marrow (BM) histology, some of the patients who were previously diagnosed with essen- tial thrombocythemia (ET) were accepted as early/prefibrotic PMF in recent publications. The aim of this study was to explore actual rate of pre-PMF according to the 2016 revised WHO criteria. Demographic characteristics of 160 patients diagnosed with ET between 2000-2017; laboratory values; cytogenetic profile; the treatments using; disease-related thromboembolic complications; progression of the disease to MF and AML; mortality rates and cause were recorded retrospectively. The diagnosis of pre-PMF or ET was con- firmed by BM morphology and clinical follow-up. BM biopsy samples obtained during the initial diagnosis were available in 107 cases. 53 cases with inaccessible BM biopsies were excluded from the study. The distribution of female/male in cases of ET was 46/28. The incidence of progression to AML was higher in pre-PMF patients. (Progression to AML: PMF 15.15%; ET 4.05%; p= 0.044). The mean duration of progression-free survival in patients with progression to AML or PMF in pre-PMF patients was 52.1±7.37 months; ET was 62.44±10.20 months. Approximately 30% of patients previously diagnosed with ET consisted of pre-PMF patients. Anemia, high LDH level, and splenomegaly are parameters that can be used in the differential diagnosis of PMF.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO clas- sification and diagnostic criteria for myeloproliferative neo - plasms: document summary and in-depth discussion. Blood Cancer J 8: 15, 2018.
- 2. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neo - plasms and acute leukemia. Blood 127: 2391-405, 2016.
- 3. Thiele J, Kvasnicka HM, Müllauer L, et al. Essential throm - bocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood 117: 5710- 5718, 2011.
- 4. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly in- fluenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29: 3179-3184, 2011.
- .5. Kamiunten A, Shide K, Kameda T, et al. Early/prefibrotic pri - mary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia. Int J Hematol 108: 411-415. 2018.
- 6. Haznedaroglu IC. The therapeutic goals of essential throm - bocythemia under the clouds of over-treatment and under- treatment. Expert Opin Pharmacother 14: 1431-1436, 2013.
- 7. Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk fac - tors for bleeding in 1104 patients with essential thrombo - cythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 26: 716-719. 2012.
- 8. How J, Hobbs GS. A Practical Guide for Using Myelofibrosis Prognostic Models in the Clinic. J Natl Compr Canc Netw 18: 1271-1278. 2020.
- 9. Tefferi A, Vardiman JW. Classification and diagnosis of my- eloproliferative neoplasms: the 2008 World Health Organiza - tion criteria and point-of-care diagnostic algorithms. Leuke - mia 22: 14-22, 2008.
- 10. Jang MA, Seo MY, Choi KJ, et al. A Rare case of essential thrombocythemia with coexisting JAK2 and MPL driver muta- tions. J Korean Med Sci 35: e168, 2020.
- 11. Soliman EA, El-Ghlban S, El-Aziz SA, et al. JAK2, CALR, and MPL mutations in Egyptian patients with classic Philadelphia- negative myeloproliferative neoplasms. Clin Lymphoma My - eloma Leuk 20: e645-e651, 2020.
- 12. Gianelli U, Vener C, Bossi A, et al. The European Consensus on grading of bone marrow fibrosis allows a better prognosti- cation of patients with primary myelofibrosis. Mod Pathol 25: 1193-202, 2012.
- 13. Barbui T, Thiele J, Ferrari A, et al. The new WHO classification for essential thrombocythemia calls for revision of available evidences. Blood Cancer J 10: 22, 2020.
- 14. Tefferi A, Barbui T. Polycythemia vera and essential thrombo- cythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 92: 94-108, 2017.
- 15. Rumi E, Boveri E, Bellini M, et al. Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. On - cotarget 8: 101735-101744, 2017.
- 16. Jeryczynski G, Thiele J, Gisslinger B, et al. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombo - cythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol 92: 885-891, 2017.
- 17. Zaidi U, Sufaida G, Rashid M, et al. A distinct molecular mu - tational profile and its clinical impact in essential thrombo - cythemia and primary myelofibrosis patients. BMC Cancer 20: 205, 2020.
- 18. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of my - eloid neoplasms and acute leukemia: rationale and important changes. Blood 114: 937-951, 2009.
- .19. Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 117: 2813-2816. 2011.
- 20. Ding J, Komatsu H, Wakita A, et al. Familial essential throm - bocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103: 4198-200, 2004.
- 21. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108: 3472-3476, 2006.
- 22. Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood 127: 333-342, 2016.
- 23. Buxhofer-Ausch V, Gisslinger H, Thiele J, et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO- defined early/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol 87: 669-672, 2012.
- 24. Finazzi G, Vannucchi AM, Barbui T. Prefibrotic myelofibrosis: treatment algorithm 2018. Blood Cancer J 8: 104, 2018.
| APA | aktimur s, Bayçelebi D, Güneş A, Yıldız L, TURGUT M (2021). WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia. , 139 - 145. 10.4999/uhod.215031 |
| Chicago | aktimur sude hatun,Bayçelebi Deniz,Güneş Ahmet Kürşad,Yıldız Levent,TURGUT Mehmet WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia. (2021): 139 - 145. 10.4999/uhod.215031 |
| MLA | aktimur sude hatun,Bayçelebi Deniz,Güneş Ahmet Kürşad,Yıldız Levent,TURGUT Mehmet WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia. , 2021, ss.139 - 145. 10.4999/uhod.215031 |
| AMA | aktimur s,Bayçelebi D,Güneş A,Yıldız L,TURGUT M WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia. . 2021; 139 - 145. 10.4999/uhod.215031 |
| Vancouver | aktimur s,Bayçelebi D,Güneş A,Yıldız L,TURGUT M WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia. . 2021; 139 - 145. 10.4999/uhod.215031 |
| IEEE | aktimur s,Bayçelebi D,Güneş A,Yıldız L,TURGUT M "WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia." , ss.139 - 145, 2021. 10.4999/uhod.215031 |
| ISNAD | aktimur, sude hatun vd. "WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia". (2021), 139-145. https://doi.org/10.4999/uhod.215031 |
| APA | aktimur s, Bayçelebi D, Güneş A, Yıldız L, TURGUT M (2021). WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia. Uluslararası Hematoloji-Onkoloji Dergisi, 31(3), 139 - 145. 10.4999/uhod.215031 |
| Chicago | aktimur sude hatun,Bayçelebi Deniz,Güneş Ahmet Kürşad,Yıldız Levent,TURGUT Mehmet WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia. Uluslararası Hematoloji-Onkoloji Dergisi 31, no.3 (2021): 139 - 145. 10.4999/uhod.215031 |
| MLA | aktimur sude hatun,Bayçelebi Deniz,Güneş Ahmet Kürşad,Yıldız Levent,TURGUT Mehmet WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia. Uluslararası Hematoloji-Onkoloji Dergisi, vol.31, no.3, 2021, ss.139 - 145. 10.4999/uhod.215031 |
| AMA | aktimur s,Bayçelebi D,Güneş A,Yıldız L,TURGUT M WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia. Uluslararası Hematoloji-Onkoloji Dergisi. 2021; 31(3): 139 - 145. 10.4999/uhod.215031 |
| Vancouver | aktimur s,Bayçelebi D,Güneş A,Yıldız L,TURGUT M WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia. Uluslararası Hematoloji-Onkoloji Dergisi. 2021; 31(3): 139 - 145. 10.4999/uhod.215031 |
| IEEE | aktimur s,Bayçelebi D,Güneş A,Yıldız L,TURGUT M "WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia." Uluslararası Hematoloji-Onkoloji Dergisi, 31, ss.139 - 145, 2021. 10.4999/uhod.215031 |
| ISNAD | aktimur, sude hatun vd. "WHO 2016 Prefibrotic Myelofibrosis in the Patients with WHO 2008 Essential Thrombocythemia". Uluslararası Hematoloji-Onkoloji Dergisi 31/3 (2021), 139-145. https://doi.org/10.4999/uhod.215031 |
